US009248191B2

(12) **United States Patent**
Acheampong et al.

(10) **Patent No.: US 9,248,191 B2**
(45) **Date of Patent: *Feb. 2, 2016**

(54) **METHODS OF PROVIDING THERAPEUTIC EFFECTS USING CYCLOSPORIN COMPONENTS**

(71) Applicant: **Allergan, Inc.**, Irvine, CA (US)

(72) Inventors: **Andrew Acheampong**, Irvine, CA (US); **Diane D. Tang-Liu**, Las Vegas, NV (US); **James N. Chang**, Newport Beach, CA (US); **David F. Power**, San Clemente, CA (US)

(73) Assignee: **Allergan, Inc.**, Irvine, CA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **14/222,478**

(22) Filed: **Mar. 21, 2014**

(65) **Prior Publication Data**

US 2014/0206626 A1 Jul. 24, 2014

Related U.S. Application Data

(63) Continuation of application No. 13/961,828, filed on Aug. 7, 2013, now Pat. No. 8,685,930, which is a continuation of application No. 11/897,177, filed on Aug. 28, 2007, now Pat. No. 8,618,064, and a continuation of application No. 10/927,857, filed on Aug. 27, 2004, now abandoned.

(60) Provisional application No. 60/503,137, filed on Sep. 15, 2003.

(51) **Int. Cl.**

A61K 38/13	(2006.01)
A61K 47/02	(2006.01)
A61K 9/00	(2006.01)
A61K 47/44	(2006.01)
A61K 9/107	(2006.01)
A61K 47/10	(2006.01)
A61K 47/22	(2006.01)
A61K 47/32	(2006.01)

(52) **U.S. Cl.**

CPC ***A61K 47/02*** (2013.01); ***A61K 9/0048*** (2013.01); ***A61K 9/107*** (2013.01); ***A61K 38/13*** (2013.01); ***A61K 47/10*** (2013.01); ***A61K 47/22*** (2013.01); ***A61K 47/32*** (2013.01); ***A61K 47/44*** (2013.01)

(58) **Field of Classification Search**

None

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

3,278,447	A	10/1966	McNicholas
4,347,238	A	8/1982	Hollingsbee
4,388,229	A	6/1983	Fu
4,388,307	A	6/1983	Cavanak
4,614,736	A	9/1986	Delevallee et al.
4,649,047	A	3/1987	Kaswan
4,764,503	A	8/1988	Wenger
4,814,323	A	3/1989	Andrieu et al.
4,839,342	A	6/1989	Kaswan
4,970,076	A	11/1990	Horrobin
4,990,337	A	2/1991	Kurihara et al.
4,996,193	A	2/1991	Hewitt et al.
5,011,681	A	4/1991	Ciotti et al.
5,047,396	A	9/1991	Orban et al.
5,051,402	A	9/1991	Kurihara et al.
5,053,000	A	10/1991	Booth et al.
5,075,104	A	12/1991	Gressel et al.
5,286,730	A	2/1994	Caufield et al.
5,286,731	A	2/1994	Caufield et al.
5,294,604	A	3/1994	Nussenblatt et al.
5,296,158	A	3/1994	MacGilp et al.
5,342,625	A	8/1994	Hauer et al.
5,364,632	A	11/1994	Benita et al.
5,368,854	A	11/1994	Rennick
5,411,952	A	5/1995	Kaswan
5,424,078	A	6/1995	Dziabo
5,441,732	A	8/1995	Hoeg et al.
5,474,919	A	12/1995	Chartrain et al.
5,474,979	A	12/1995	Ding et al.
5,496,811	A	3/1996	Aviv et al.
5,504,068	A	4/1996	Komiya et al.
5,540,931	A	7/1996	Hewitt et al.
5,543,393	A	8/1996	Kim et al.
5,578,586	A	11/1996	Glonek et al.

(Continued)

FOREIGN PATENT DOCUMENTS

DE	19810655	9/1999
EP	0448856	10/1991

(Continued)

OTHER PUBLICATIONS

Abdulrazik, M. et al, Ocular Delivery of Cyclosporin A II. Effect of Submicron Emulsion's Surface Charge on Ocular Distribution of Topical Cyclosporin A, S.T.P. Pharma Sciences, Dec. 2001, 427-432, 11(6).

(Continued)

Primary Examiner — Marcela M Cordero Garcia

(74) *Attorney, Agent, or Firm* — Laura L. Wine; Joel B. German; Debra D. Condino

(57) **ABSTRACT**

Methods of treating an eye of a human or animal include administering to an eye of a human or animal a composition in the form of an emulsion including water, a hydrophobic component and a cyclosporin component in a therapeutically effective amount of less than 0.1% by weight of the composition. The weight ratio of the cyclosporin component to the hydrophobic component is less than 0.8.

27 Claims, No Drawings